Business Summary

Shire is a holding company. The Company and its subsidiaries is a biopharmaceutical company focused on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT), and regenerative medicine (RM) as well as other therapeutic areas. The Company has three segments: Specialty Pharmaceuticals, which includes VYVANSE/VENVANSE, ADDERALL XR, INTUNIV, and EQUASYM for the treatment of ADHD, as well as LIALDA, PENTASA and RESOLOR for the treatment of GI; HGT, which includes REPLAGAL for Fabry disease, ELAPRASE for Hunter syndrome, VPRIV for Gaucher disease, and FIRAZYR for Hereditary angioedema; and RM, which consist of DERMAGRAFT for diabetic food ulcers.

Data provided by Mergent, Inc.

Recent Company News

Powered by Interactive Data Managed Solutions

Recent / Upcoming DR Events

Data provided by Thomson Reuters, Inc.
DR Symbol SHPG
CUSIP 82481R106
DR Exchange NASDAQ Stock Market
DR ISIN US82481R1068
Ratio DR:ORD 1:3
Depositary CIT (Sponsored)
Effective Date May 12, 2011
Country United Kingdom
Industry Pharma. & Biotech.

Powered by Interactive Data Managed Solutions

Monthly DR Trading Summary

Month Month End
DR Close
Price		 DR Trading Volume Avg Day DR
Trading
Volume
May. 13 98.47 20,663,151 939,234
Apr. 13 93.64 11,634,260 528,830
Mar. 13 91.36 7,812,089 390,604
Data provided by Interactive Data Corp.

This DR is a Constituent of the following BNY Mellon DR Indices:

ADR Index

DR Index

Classic ADR Index

Related links

Helpful Links
This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE

© 2013 The Bank of New York Mellon Corporation. Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Quotes delayed at least 15 minutes.Market data provided by Interactive Data
Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

Certain information included in this website is proprietary to Mergent, Inc. (Mergent) Copyright © 2003-2010. Reproduction of such information in any form is prohibited. Because of the possibility of
human or mechanical error by Mergent's sources, Mergent or others, Mergent does not guarantee the accuracy, adequacy, completeness, timeliness or availability or for the results obtained from the
use of such information. Mergent Terms of Use apply

Holdings information provided by FactSet Research Systems Inc. Copyright © 2003-2013 FactSet Research Systems Inc. All rights reserved.

DR Calendar provided by Thomson Reuters, Inc. © 2013 The Thomson Reuters Corporation. All Rights Reserved. Terms of Use. Privacy Statement.
Send questions, comments or suggestions to corporateservices@thomsonreuters.com